http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011250800-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 |
| filingDate | 2011-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bccc1fe2c7c55ba899746a39573dbfe5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cccac84f881c57474bb68d58deec0a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1339ead8e739c72adc43053f7e31e460 |
| publicationDate | 2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2011250800-A1 |
| titleOfInvention | Methods for inhibition of NKT cells |
| abstract | The present invention is directed to molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function. Said molecules are administered to patients for treatment of conditions such as systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiments of the invention, the inhibitory agent is an anergizing glycolipid, for example galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation. |
| priorityDate | 2004-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 420.